成人 SCD 患者造血细胞移植后发生髓系恶性肿瘤的基线 TP53 突变。
Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation.
机构信息
Laboratory of Myeloid Malignancies, Hematology Branch, and.
Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
出版信息
Blood. 2020 Apr 2;135(14):1185-1188. doi: 10.1182/blood.2019004001.
Abstract
There is a Commentary on this article in this issue.
摘要
本期有对这篇文章的评论。
相似文献
1
Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation.成人 SCD 患者造血细胞移植后发生髓系恶性肿瘤的基线 TP53 突变。
Blood. 2020 Apr 2;135(14):1185-1188. doi: 10.1182/blood.2019004001.
2
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.骨髓增生异常综合征和继发性急性髓系白血病中的基因异常：对干细胞移植结果的影响。
Blood. 2017 Apr 27;129(17):2347-2358. doi: 10.1182/blood-2016-12-754796. Epub 2017 Feb 21.
3
Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.伴有 17 号染色体异常的急性髓系白血病或骨髓增生异常综合征，以及造血干细胞移植与否的长期预后。
Leuk Res. 2020 Aug;95:106402. doi: 10.1016/j.leukres.2020.106402. Epub 2020 Jun 18.
4
Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with mutations.影响伴有突变的急性髓系白血病/骨髓增生异常综合征患者异基因移植后生存的预后因素。
Blood. 2018 Jun 28;131(26):2989-2992. doi: 10.1182/blood-2018-02-832360. Epub 2018 May 16.
5
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.淋巴瘤自体干细胞移植后与不良预后相关的克隆性造血
J Clin Oncol. 2017 May 10;35(14):1598-1605. doi: 10.1200/JCO.2016.71.6712. Epub 2017 Jan 9.
6
Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.治疗相关性骨髓增生异常综合征和急性髓系白血病的突变分析。
Haematologica. 2013 Jun;98(6):908-12. doi: 10.3324/haematol.2012.076729. Epub 2013 Jan 24.
7
Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither.基因治疗镰状细胞病后的白血病：插入突变，白消安，还是两者都不是。
Blood. 2021 Sep 16;138(11):942-947. doi: 10.1182/blood.2021011488.
8
Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease.目前关于镰状细胞病造血细胞移植后继发恶性肿瘤的知识。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):266-271. doi: 10.1182/hematology.2022000371.
9
Myelodysplasia and acute myelogenous leukemia after myeloablative therapy with autologous stem-cell transplantation.自体干细胞移植清髓治疗后的骨髓发育异常和急性髓性白血病。
J Clin Oncol. 1994 Dec;12(12):2521-3. doi: 10.1200/JCO.1994.12.12.2521.
10
What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia?TP53 基因突变型骨髓增生异常综合征和急性髓系白血病的治疗前景如何？
Cancer J. 2022;28(1):51-61. doi: 10.1097/PPO.0000000000000569.
引用本文的文献
1
To pursue gene therapy or not? Is it feasible after graft failure in allogeneic hematopoietic cell transplant recipients.是否进行基因治疗？对于异基因造血细胞移植受者移植失败后是否可行？
Blood Adv. 2025 Aug 12;9(15):3845-3852. doi: 10.1182/bloodadvances.2024015413.
2
Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy.用于基因治疗的造血干细胞和祖细胞的体外修饰
Mol Ther. 2025 May 7;33(5):2141-2153. doi: 10.1016/j.ymthe.2025.03.058. Epub 2025 Apr 1.
3
Selecting patients with sickle cell disease for gene addition or gene editing-based therapeutic approaches: Report on behalf of a joint EHA Specialized Working Group and EBMT Hemoglobinopathies Working Party consensus conference.为基于基因添加或基因编辑的治疗方法选择镰状细胞病患者：代表欧洲血液学协会（EHA）专门工作组和欧洲血液与骨髓移植协会（EBMT）血红蛋白病工作组联合共识会议撰写的报告
Hemasphere. 2025 Mar 13;9(3):e70089. doi: 10.1002/hem3.70089. eCollection 2025 Mar.
4
Current and future treatments for sickle cell disease: From hematopoietic stem cell transplantation to in vivo gene therapy.镰状细胞病的当前及未来治疗方法：从造血干细胞移植到体内基因治疗。
Mol Ther. 2025 May 7;33(5):2172-2191. doi: 10.1016/j.ymthe.2025.03.016. Epub 2025 Mar 12.
5
Long-term tracking of haematopoietic clonal dynamics and mutations in non-human primate undergoing transplantation of lentivirally barcoded haematopoietic stem and progenitor cells.对接受慢病毒条形码标记造血干细胞和祖细胞移植的非人灵长类动物的造血克隆动态和突变进行长期跟踪。
Br J Haematol. 2024 Dec;205(6):2487-2497. doi: 10.1111/bjh.19889. Epub 2024 Nov 10.
6
T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities.接受嵌合抗原受体T细胞（CAR-T）治疗患者中的T细胞淋巴瘤：评估风险和因果关系
Blood. 2024 Dec 12;144(24):2473-2481. doi: 10.1182/blood.2024025828.
7
How I treat sickle cell disease with gene therapy.我如何用基因疗法治疗镰状细胞病。
Blood. 2024 Dec 26;144(26):2693-2705. doi: 10.1182/blood.2024024519.
8
A simplified G-CSF-free procedure allows for in vivo HSC gene therapy of sickle cell disease in a mouse model.一种简化的无 G-CSF 程序可实现活体 HSC 基因治疗镰状细胞病的小鼠模型。
Blood Adv. 2024 Aug 13;8(15):4089-4101. doi: 10.1182/bloodadvances.2024012757.
9
TP53 mutation screening for patients at risk of myeloid malignancy.对有髓系恶性肿瘤风险的患者进行TP53基因突变筛查。
Leukemia. 2024 Jul;38(7):1604-1608. doi: 10.1038/s41375-024-02283-x. Epub 2024 May 25.
10
Is There any Relationship Between the Repeated Complications of Sickle Cell Disease and the Potential Development of Acute Leukemia?镰状细胞病的反复并发症与急性白血病的潜在发展之间是否存在关联？
Oncol Ther. 2024 Jun;12(2):233-238. doi: 10.1007/s40487-024-00274-7. Epub 2024 Mar 29.
本文引用的文献
1
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.有残留疾病基因组证据的急性髓细胞性白血病异体移植的条件强度的影响。
J Clin Oncol. 2020 Apr 20;38(12):1273-1283. doi: 10.1200/JCO.19.03011. Epub 2019 Dec 20.
2
Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient.羟基脲治疗镰状细胞病患者中急性髓系白血病的发生。
Cancer Biol Ther. 2019;20(11):1389-1397. doi: 10.1080/15384047.2019.1647055. Epub 2019 Aug 18.
3
Myeloid neoplasms in the setting of sickle cell disease: an intrinsic association with the underlying condition rather than a coincidence; report of 4 cases and review of the literature.镰状细胞病患者的骨髓增生性肿瘤：与基础疾病有内在关联而非巧合；4 例报告并文献复习。
Mod Pathol. 2019 Dec;32(12):1712-1726. doi: 10.1038/s41379-019-0325-6. Epub 2019 Aug 1.
4
Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity.长期使用羟基脲对镰状细胞贫血患者是否安全？关于遗传毒性和致突变性的阐述。
Environ Mol Mutagen. 2019 Apr;60(3):302-304. doi: 10.1002/em.22260. Epub 2018 Dec 7.
5
Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT.环磷酰胺可改善患有镰状细胞病且有严重器官损伤并接受单倍体相合外周血干细胞移植的患者的植入情况。
Blood Adv. 2017 Apr 19;1(11):652-661. doi: 10.1182/bloodadvances.2016002972. eCollection 2017 Apr 25.
6
Increased risk of leukemia among sickle cell disease patients in California.加利福尼亚州镰状细胞病患者患白血病的风险增加。
Blood. 2017 Sep 28;130(13):1597-1599. doi: 10.1182/blood-2017-05-783233. Epub 2017 Aug 22.
7
Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease.羟基脲治疗的镰状细胞病单倍体相合移植后白血病加速转化
Leuk Lymphoma. 2018 Jan;59(1):241-244. doi: 10.1080/10428194.2017.1324158. Epub 2017 Jun 7.
8
Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study.镰状细胞病患者患个体恶性肿瘤的风险：英国全国记录链接研究
J R Soc Med. 2016 Aug;109(8):303-9. doi: 10.1177/0141076816651037. Epub 2016 Jun 20.
9
Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia.患有克隆性细胞遗传学异常的骨髓增生异常综合征，在因镰状细胞贫血接受羟基脲治疗14年后继发致命性红系白血病。
Am J Hematol. 2015 Jul;90(7):E131-2. doi: 10.1002/ajh.24010.
10
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.TP53突变在治疗相关急性髓系白血病的起源与演变中的作用
Nature. 2015 Feb 26;518(7540):552-555. doi: 10.1038/nature13968. Epub 2014 Dec 8.
Zotero 插件